Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2013

Filing Date
Filed February 28, 2014
Period End
December 31, 2013
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed February 28, 2014. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. is a science-driven biopharmaceutical company focused on human enzymes that alter the extracellular matrix, with its core technology built on rHuPH20, a recombinant human hyaluronidase.

Its only marketed proprietary product is Hylenex recombinant, and its value depends heavily on collaborations with Roche, Pfizer, Baxter and Intrexon. For 2013, total revenues were $54.8 milliona (versus $42.3 million in 2012), driven by product sales of $24.4 million and revenues under collaborative agreements of $30.4 million. The company reported a net loss of $83.5 million ($0.74 per share), up from $53.6 million in 2012, and an accumulated deficit of $382.1 million as of December 31, 2013.

The balance sheet weakened over the year. Cash, cash equivalents and marketable securities fell to $71.5 millionb from $99.5 million, and stockholders' deficit was $20.0 million compared with equity of $48.9 million a year earlier. Long-term debt rose to $49.8 million after the December 2013 amended loan agreement increased the term loan to $50 million, maturing January 1, 2018.

Management stated that existing cash is sufficient for at least the next twelve months, excluding the February 2014 offering, and it anticipates net cash burn of approximately $45 to $55 millionc for 2014. The company completed an underwritten offering of 8,846,153 shares at $13.00 per share in February 2014, generating about $107.8 million in net proceeds.

Key 2014 catalysts include top-line CONSISTENT 1 results for the ultrafast insulin program expected in the first quarter, HTI-501 data at three and six months, and PEGPH20 Phase 2 enrollment expected to complete in the second half. Risks flagged in the filing include FDA questions about non-neutralizing anti-rHuPH20 antibodies that led to a complete response letter for Baxter's HyQvia, the termination of the ViroPharma collaboration in February 2014, and dependence on contract manufacturers Avid and Cook.

Key Highlights

  1. Total revenues were $54.8 million in 2013, up from $42.3 million in 2012, with product sales rising to $24.4 million from $2.9 million.
  2. Net loss widened to $83.5 million, or $0.74 per share, from $53.6 million, or $0.48 per share, in 2012; accumulated deficit reached $382.1 million.
  3. Stockholders' deficit was $20.0 million at year-end 2013, compared with stockholders' equity of $48.9 million at year-end 2012.
  4. Cash, cash equivalents and marketable securities totaled $71.5 million at December 31, 2013; a February 2014 offering raised about $107.8 million in net proceeds.
  5. Long-term debt increased to $49.8 million after the December 2013 Amended and Restated Loan Agreement brought the term loan to $50 million, maturing January 1, 2018.
  6. Roche accounted for 64% of 2013 total revenues, and Herceptin SC and HyQvia European approvals drove bulk rHuPH20 product sales of $14.8 million.
  7. Management projects 2014 net cash burn of approximately $45 to $55 million excluding the February 2014 financing, and expects CONSISTENT 1 top-line results in the first quarter of 2014.

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$54.80M$42.33M+29.5%
Cost of Revenue$6.25M$1.09M+470.9%
Gross Profit$48.55M$41.23M+17.8%
R&D Expenses$96.64M$70.04M+38.0%
SG&A Expenses$32.35M$24.81M+30.4%
Operating Expenses$135.23M$95.95M+40.9%
Operating Income-$80.43M-$53.63M−50.0%
Interest Expense$3.30M$0—
Net Income-$83.48M-$53.55M−55.9%
EPS (Basic)$-0.74$-0.48−54.2%
Shares Outstanding (Basic)112.81M111.08M+1.6%

Frequently Asked Questions

  1. How much cash does Halozyme have and how long will it last?

    Cash, cash equivalents and marketable securities were $71.5 million at December 31, 2013. Management believes these resources will fund operations for at least the next twelve months, and that statement excludes roughly $107.8 million in net proceeds from the February 2014 public offering. For 2014, the company anticipates net cash burn of approximately $45 to $55 million, depending on program progress and milestones.

  2. What drove the increase in revenue in 2013?

    Product sales increased to $24.4 million from $2.9 million, primarily because of $14.8 million in bulk rHuPH20 product sales for Herceptin SC and HyQvia following their 2013 European approvals, plus a $6.8 million increase in Hylenex recombinant sales. Revenues under collaborative agreements fell to $30.4 million from $39.4 million.

  3. What are the main near-term catalysts for Halozyme?

    The company plans to report top-line results from the CONSISTENT 1 study of Hylenex recombinant in Type 1 diabetes pump therapy in the first quarter of 2014, and expects top-line HTI-501 data at three and six months in the first quarter of 2014. Enrollment in the Phase 2 PEGPH20 pancreatic cancer study is expected to complete in the second half of 2014.

  4. What risks did the filing highlight regarding the company's collaborations?

    The FDA issued a complete response letter for Baxter's HyQvia BLA in August 2012 over non-neutralizing anti-rHuPH20 antibodies, and the agency has asked that patients no longer be dosed with rHuPH20 in the Baxter program pending additional data. ViroPharma discontinued its Cinryze study and terminated its collaboration with Halozyme in February 2014. The filing also notes that the company depends on collaborators for most of its revenue and on contract manufacturers Avid and Cook for bulk rHuPH20.

  5. What is the status of the company's debt?

    On December 27, 2013, Halozyme entered into an Amended and Restated Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank that extended the original $30 million term loan and added $20 million, for a total of $50 million. The loan carries a 7.55% fixed interest rate, matures January 1, 2018, and is secured by substantially all assets other than intellectual property. The filing states the company was in compliance with all material covenants as of December 31, 2013.